[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599397":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":74,"collaborators":20,"id":76,"slug":20,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":20,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":20,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":20,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Ouro Medicines","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"OM336 Dose Escalation","EXPERIMENTAL","Participants will receive OM336 via subcutaneous injection in ascending dose cohorts",[13],"Drug: OM336",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","OM336","OM336 is an engineered bispecific antibody directed against BCMA and CD3",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Study Sponsor","CONTACT","415-429-4887","info@ouromeds.com",[28,46,60],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"The Canberra Hospital","RECRUITING","Canberra","Australian Capital Territory","2605","Australia",{"type":36,"coordinates":37},"Point",[38,39],149.12807,-35.28346,{"lat":39,"lon":38},[42],{"name":43,"role":24,"phone":44,"phoneExt":20,"email":45},"Clinical Research Coordinator","+61 2 5124 4338","Ryshelle.kilby@act.gov.au",{"facility":47,"status":30,"city":48,"state":49,"zip":50,"country":34,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"Liverpool Hospital","Sydney","New South Wales","2107",{"type":36,"coordinates":52},[53,54],151.20732,-33.86785,{"lat":54,"lon":53},[57],{"name":43,"role":24,"phone":58,"phoneExt":20,"email":59},"+61 474 279 274","pinky.patel@health.nsw.gov.au",{"facility":61,"status":30,"city":62,"state":63,"zip":64,"country":34,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Icon Cancer Center South Brisbane","Brisbane","Queensland","4066",{"type":36,"coordinates":66},[67,68],153.02809,-27.46794,{"lat":68,"lon":67},[71],{"name":43,"role":24,"phone":72,"phoneExt":20,"email":73},"+61 7 3737 4795","Annabelle.morton@icon.team",{"type":75,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100599397",false,"NCT07083960","OM336 in Autoimmune Cytopenias","An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Autoimmune Cytopenias","Key Inclusion Criteria:\n\n* Active autoimmune cytopenia\n* Relapsed\u002Frefractory after ≥1 prior treatment\n* Body weight ≥ 55 kg\n* Willing to comply with and study requirements and procedures\n\nKey Exclusion Criteria:\n\n* Previous treatment with a BCMA-targeted therapy\n* Clinically significant infection within 3 months of screening\n* Major surgery or splenectomy within 3 months of screening or planned during the study\n* Pregnant or breastfeeding","ALL","18 Years","75 Years",{"count":86,"type":87},32,"ESTIMATED","INTERVENTIONAL",[90],"PHASE1","An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.",[93,94,95],"AIHA - Warm Autoimmune Hemolytic Anemia","AIHA - Cold Autoimmune Hemolytic Anemia","ITP - Immune Thrombocytopenia","2025-09-24",{"date":98,"type":99},"2025-09-30","ACTUAL",{"date":101,"type":99},"2025-08-01",{"date":103,"type":87},"2027-09",{"name":5,"class":6},3]